Evaluating the diagnostic role of in-bore magnetic resonance imaging guided prostate biopsy: a single-centre study.

Furrer, Marc A; Hong, Anne; Wetherell, David; Heinze, Stefan B; Simkin, Paul; Chow, Ken; Lawrentschuk, Nathan; Zargar, Homayoun (2022). Evaluating the diagnostic role of in-bore magnetic resonance imaging guided prostate biopsy: a single-centre study. ANZ journal of surgery, 92(6), pp. 1486-1491. Wiley 10.1111/ans.17713

[img]
Preview
Text
ANZ_Journal_of_Surgery_-_2022_-_Furrer_-_Evaluating_the_diagnostic_role_of_in_bore_magnetic_resonance_imaging_guided.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (250kB) | Preview

BACKGROUND

To evaluate the role of in-bore MRI-guided biopsy (IB-MRGB) in the diagnosis of clinically significant prostate cancer (csPCa).

METHODS

In this tertiary single centre study, a total of 125 consecutive patients receiving IB-MRGB over a three-year period were evaluated, including 73 patients who had prior biopsies and 52 biopsy-naïve patients. We assessed cancer detection rate of patients according to the degree of suspicion based on mpMRI findings. Histopathological data were reviewed by experienced uropathologists.

RESULTS

The mpMRI was suspicious for PCa (PI-RADS 4/5) in 77% (96/125) and equivocal (PI-RADS 3) in 23% (29/125). The detection rate for csPCa was 54.2% (52/96) and 20.7% (6/29) for suspicious lesions (PI-RADS 4/5) and equivocal lesions (PI-RADS 3), respectively. In subgroup analysis, patients with previous negative biopsy, overall positive biopsy rate and csPCa detection rate were 48.3% (19/35) and 34.5% (13/35), respectively. In patients on AS, 36/44 (81.8%) and 21/44 (47.8%) had PCa and csPCa respectively. In biopsy-naïve patients 34/52 (65.4%) and 27/52 (51.92%) had PCa and csPCa respectively. Of the patients on AS, 18/44 (41.6%) upgraded from ISUP 1 to ISUP 2 PCa, and 4/44 (9.1%) upgraded from ISUP 1 to ISUP 3 PCa on IB-MRGB. A total of 14 Clavien-Dindo≤2 complications occurred in 14 patients (11.2%) that were directly related to the biopsy. No Clavien-Dindo≥3 complications occurred.

CONCLUSION

MRI-targeted biopsy is suitable for assessment of csPCa. Given the favourable complications profile, its use may be considered in both the initial biopsy and re-biopsy settings.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Furrer, Marc

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1445-2197

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

29 Apr 2022 10:47

Last Modified:

05 Dec 2022 16:19

Publisher DOI:

10.1111/ans.17713

PubMed ID:

35482421

Uncontrolled Keywords:

MRI-guided biopsy in-bore biopsy multiparametric MRI prostate cancer

BORIS DOI:

10.48350/169622

URI:

https://boris.unibe.ch/id/eprint/169622

Actions (login required)

Edit item Edit item
Provide Feedback